Research Article
Autoantibodies to NR2A Peptide of the Glutamate/NMDA Receptor in Patients with Seizure Disorders in Neuropsychiatric Systemic Lupus Erythematosus
Table 2
Comparison of clinical characteristics between NPSLE and non-NPSLE in active SLE patients.
| | | Active SLE | Test value | value | | | NPSLE () | Non-NPSLE () |
| | Number of males/females | 4/32 | 5/32 | 0.097 | 0.755 | | Age (years), median (range) | 25 (18 to 60) | 34 (19 to 62) | −2.973 | | | SLEDAI, median (range) | 17 (8 to 30) | 9 (5 to 14) | 9.174 | | | Seizure, | 17 (47%) | 0 | 22.776 | | | ANA (U/mL), median (range) | 175.0 (45.8 to 696.9) | 146.5 (66.6 to 873.7) | 0.366 | 0.716 | | Anti-dsDNA (U/mL), median (range) | 218.3 (21.6 to 747.5) | 57.1 (31.6 to 115.3) | 6.736 | | | Anti-ribosomal P antibodies, | 14 (39%) | 12 (32%) | 0.332 | 0.565 | | SSA, | 20 (56%) | 18 (49%) | 0.349 | 0.555 | | SSB, | 6 (17%) | 8 (22%) | 0.289 | 0.591 | | C3 (g/L), median (range) | 0.35 (0.13 to 1.53) | 0.33 (0.23 to 1.08) | −0.732 | 0.467 | | C4 (g/L), median (range) | 0.06 (0.01 to 0.33) | 0.01 (0.01 to 0.33) | 0.014 | 0.989 | | Number with/without treatment | 32/4 | 26/11 | | | | Users of prednisone (%) | 19 (53%) | 23 (62%) | 0.658 | 0.417 | | Dose (mg/day), median (range) | 15 (2.5 to 100) | 10 (2.5 to 80) | | | | Users of hydroxychloroquine (%) | 20 (56%) | 21 (57%) | 0.057 | 0.812 | | Dose (mg/day), median (range) | 400 (150 to 400) | 400 (200 to 400) | | |
|
|
